Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes
Saved in:
| Main Authors: | Liliana Italia De Rosa, Martina Catania, Kristiana Kola, Michele Paolisi, Pierpaolo Bianca, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925003444 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Detection Matters: Bridging Evidence and Practice, a Call for Enhanced Cardiovascular Screening in ADPKD
by: Martina Catania, et al.
Published: (2025-02-01) -
Understanding Familial Variability in ADPKD: A Comprehensive Approach Integrating Genetics, Hormones, and Lifestyle for Tailored Management
by: Martina Catania, et al.
Published: (2025-01-01) -
Response to the Letter to the Editor Entitled “Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes”
by: Neera K. Dahl, et al.
Published: (2025-08-01) -
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5
by: Akinari Sekine, et al.
Published: (2025-06-01) -
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]
by: Kiyotaka Uchiyama, et al.
Published: (2025-07-01)